Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.91)
# 220
Out of 4,651 analysts
102
Total ratings
81.8%
Success rate
53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintained: Buy | $166 | $92.00 | +80.43% | 7 | Aug 14, 2026 | |
| STRO Sutro Biopharma | Rated: Buy | $27 → $49 | $20.48 | +139.26% | 3 | Aug 13, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | $16 → $23 | $24.28 | -5.27% | 11 | Aug 12, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $37 → $40 | $25.12 | +59.24% | 8 | Aug 7, 2026 | |
| EXEL Exelixis | Rated: Hold | $49 → $50 | $51.24 | -2.42% | 5 | Aug 6, 2026 | |
| RCUS Arcus Biosciences | Rated: Hold | $23 → $26 | $29.48 | -11.80% | 9 | Aug 6, 2026 | |
| RVMD Revolution Medicines | Rated: Buy | $167 → $240 | $203.71 | +17.81% | 11 | Aug 6, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $48 | $36.30 | +32.23% | 6 | Aug 5, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Rated: Buy | $74 → $87 | $76.75 | +13.36% | 16 | Jul 29, 2026 | |
| GMAB Genmab | Rated: Buy | $40 | $31.94 | +25.23% | 7 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $19.86 | +5.74% | 9 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5 | $3.56 | +40.45% | 1 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $34.21 | +75.39% | 3 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $23.34 | +15.68% | 6 | Oct 23, 2025 |
Celcuity
Aug 14, 2026
Maintained: Buy
Price Target: $166
Current: $92.00
Upside: +80.43%
Sutro Biopharma
Aug 13, 2026
Rated: Buy
Price Target: $27 → $49
Current: $20.48
Upside: +139.26%
Bicara Therapeutics
Aug 12, 2026
Rated: Hold
Price Target: $16 → $23
Current: $24.28
Upside: -5.27%
Zymeworks
Aug 7, 2026
Maintained: Buy
Price Target: $37 → $40
Current: $25.12
Upside: +59.24%
Exelixis
Aug 6, 2026
Rated: Hold
Price Target: $49 → $50
Current: $51.24
Upside: -2.42%
Arcus Biosciences
Aug 6, 2026
Rated: Hold
Price Target: $23 → $26
Current: $29.48
Upside: -11.80%
Revolution Medicines
Aug 6, 2026
Rated: Buy
Price Target: $167 → $240
Current: $203.71
Upside: +17.81%
IDEAYA Biosciences
Aug 5, 2026
Maintained: Buy
Price Target: $48
Current: $36.30
Upside: +32.23%
Kiniksa Pharmaceuticals International,
Jul 29, 2026
Rated: Buy
Price Target: $74 → $87
Current: $76.75
Upside: +13.36%
Genmab
Jun 29, 2026
Rated: Buy
Price Target: $40
Current: $31.94
Upside: +25.23%
May 19, 2026
Maintained: Buy
Price Target: $21
Current: $19.86
Upside: +5.74%
May 13, 2026
Rated: Hold
Price Target: $5
Current: $3.56
Upside: +40.45%
Apr 14, 2026
Maintained: Buy
Price Target: $60
Current: $34.21
Upside: +75.39%
Oct 23, 2025
Maintained: Buy
Price Target: $27
Current: $23.34
Upside: +15.68%